Inhibitory effects of halothane on the thermogenic pathway in brown adipocytes: localization to adenylyl cyclase and mitochondrial fatty acid oxidation.
Volatile anesthetics such as halothane efficiently inhibit nonshivering thermogenesis as well as the cellular manifestation of that phenomenon: norepinephrine-induced respiration in brown adipocytes. To identify the molecular site(s) of action of such anesthetics, we have examined the effect of halothane on the sequential intracellular steps from the interaction of norepinephrine with isolated brown adipocytes to the stimulation of mitochondrial respiration (=thermogenesis). We did not identify an inhibition at the level of the adrenergic receptors, but a first site of inhibition was identified as the generation of cAMP by adenylyl cyclase; this led to inhibition of norepinephrine-induced expression of the uncoupling protein-1 (UCP1) gene and reduced norepinephrine-induced lipolysis as secondary effects. Although an inhibition of lipolysis in itself would inhibit thermogenesis, circumvention of this inhibition revealed that a second, postlipolytic, site of inhibition existed: halothane also inhibited the stimulatory effect of exogenous fatty acids on cellular respiration. This inhibition was independent of the presence of UCP1 in the mitochondria of the cells and was thus not directly on the thermogenic uncoupling mechanism. Since not only fatty acid oxidation but also pyruvate oxidation were inhibited by halothane in isolated mitochondria, whereas glycerol-3-phosphate oxidation was not, the second site of action of halothane, evident when cyclase/lipolytic inhibition was circumvented, was located to the respiratory chain, complex I. The results thus explain the inhibition of nonshivering thermogenesis by identifying two sites of action of halothane in brown adipocytes. In addition, the results may open for new formulations of the molecular background to anesthesia.
Ohlson
Kerstin B E
KB
The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, SE-106 91 Stockholm, Sweden.
Shabalina
Irina G
IG
Lennström
Katarina
K
Backlund
Emma C
EC
Mohell
Nina
N
Bronnikov
Gennady E
GE
Lindahl
Sten G E
SG
Cannon
Barbara
B
Nedergaard
Jan
J
D000262:Adenylyl Cyclases / Q000378:metabolism*; D017667:Adipocytes / Q000187:drug effects* / Q000378:metabolism; D002001:Adipose Tissue, Brown / Q000166:cytology; D018685:Anesthetics, Inhalation / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport; D002331:Carnitine / Q000494:pharmacology; D002352:Carrier Proteins / Q000378:metabolism; D002478:Cells, Cultured; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D004347:Drug Interactions; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006221:Halothane / Q000494:pharmacology*; D007473:Ion Channels; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D024101:Mitochondrial Proteins; D009638:Norepinephrine / Q000502:physiology; D010084:Oxidation-Reduction; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D022722:Thermogenesis / Q000187:drug effects*; D000071256:Uncoupling Protein 1
D018685:Anesthetics, Inhalation; D002352:Carrier Proteins; D005227:Fatty Acids; D007473:Ion Channels; D008565:Membrane Proteins; D024101:Mitochondrial Proteins; D011942:Receptors, Adrenergic, alpha; D000071256:Uncoupling Protein 1; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D002331:Carnitine; D006221:Halothane; D009638:Norepinephrine